Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
26.44
+0.36 (1.38%)
Oct 24, 2024, 4:00 PM EDT - Market closed

Denali Therapeutics Revenue

Denali Therapeutics had revenue of $1.27M in the twelve months ending June 30, 2024, down -99.63% year-over-year. In the year 2023, Denali Therapeutics had annual revenue of $330.53M with 204.74% growth.

Revenue (ttm)
$1.27M
Revenue Growth
-99.63%
P/S Ratio
n/a
Revenue / Employee
$2,847
Employees
445
Market Cap
3.79B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023330.53M222.07M204.74%
Dec 31, 2022108.46M59.80M122.90%
Dec 31, 202148.66M-287.00M-85.50%
Dec 31, 2020335.66M308.98M1,158.19%
Dec 31, 201926.68M-102.48M-79.35%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Oscar Health 7.23B
Surgery Partners 2.89B
Haemonetics 1.33B
Prestige Consumer Healthcare 1.11B
Axonics 408.81M
TransMedics Group 358.76M
ADMA Biologics 330.24M
Alvotech 308.73M
Revenue Rankings